BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-7868 [PMID: 26167086 DOI: 10.3748/wjg.v21.i25.7860]
URL: https://www.wjgnet.com/1007-9327/full/v21/i25/7860.htm
(348) (377) (0) (0) (11912) (132)
Number Citing Articles
1
Nahum Méndez-Sánchez, Shreya C. Pal, Jacqueline Córdova-Gallardo. How far are we from an approved drug for nonalcoholic steatohepatitis?. Expert Opinion on Pharmacotherapy 2023; 24(9) doi: 10.1080/14656566.2023.2206953
2
Vasilios G. Athyros, Niki Katsiki, Michael Doumas. Lipid association of India (LAI) expert consensus statement: part 2, specific patient categories. Clinical Lipidology 2018; 13(1) doi: 10.1080/17584299.2017.1411068
3
Cheng Han Ng, Margaret LP Teng, Nicholas WS Chew, Kai En Chan, Jie Ning Yong, Jingxuan Quek, Darren Jun Hao Tan, Wen Hui Lim, Gabriel Sheng Jie Lee, Jessica Wong, Apichat Kaewdech, Daniel Q Huang, Jiongwei Wang, Mark Y Chan, Mazen Noureddin, Mohammad Shadab Siddiqui, Arun Sanyal, Mark Muthiah. Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. Expert Review of Gastroenterology & Hepatology 2022; 16(9) doi: 10.1080/17474124.2022.2119128
4
Feliciano Chanana Paquissi. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Frontiers in Immunology 2016; 7 doi: 10.3389/fimmu.2016.00490
5
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Journal of Gastroenterology 2021; 56(11) doi: 10.1007/s00535-021-01796-x
6
Ramy Younes, Elisabetta Bugianesi. The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. Current Hepatology Reports 2018; 17(4) doi: 10.1007/s11901-018-0422-x
7
Pavel Kraml. Lipid-lowering therapy in selected specific groups of patients. Medicína pro praxi 2020; 17(3) doi: 10.36290/med.2020.029
8
Vasiliki Venetsanaki, Stergios A. Polyzos. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Current Vascular Pharmacology 2019; 17(6) doi: 10.2174/1570161116666180711121949
9
Jaime Bosch, Jordi Gracia-Sancho, Juan G Abraldes. Cirrhosis as new indication for statins. Gut 2020; 69(5) doi: 10.1136/gutjnl-2019-318237
10
И.Р. Агабабян, Ш.Ш. Садыкова. Pleyotropic Effects of Statins Non-Alcoholic Fat Disease of the Liver Non-Alcoholic Steatohepatitis. Рецепт 2022; (2) doi: 10.34883/PI.2022.25.2.006
11
Manal F. Abdelmalek. The clinical and economic burden of NAFLD: time to turn the tide. Nature Reviews Gastroenterology & Hepatology 2016; 13(12) doi: 10.1038/nrgastro.2016.178
12
I. Commins, D. Clayton-Chubb, N. Janko, A. Majeed, W. Kemp, S. K. Roberts. Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases. Medical Sciences 2026; 14(1) doi: 10.3390/medsci14010084
13
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou, Vasilios G. Athyros. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018; 12(4) doi: 10.1080/17474124.2018.1439379
14
Stergios A. Polyzos, Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee, Christos S. Mantzoros. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020; 111 doi: 10.1016/j.metabol.2020.154203
15
N Katsiki, Td Filippatos, C Vlachopoulos, D Panagiotakos, H Milionis, A Tselepis, A Garoufi, L Rallidis, D Richter, T Nomikos, G Kolovou, K Kypreos, C Chrysohoou, K Tziomalos, I Skoumas, I Koutagiar, A Attilakos, M Papagianni, C Boutari, V Kotsis, C Pitsavos, M Elisaf, K Tsioufis, E Liberopoulos. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023. Atherosclerosis Plus 2024; 55 doi: 10.1016/j.athplu.2024.01.004
16
Hersh Shroff, Lisa B. VanWagner. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. Current Hepatology Reports 2020; 19(3) doi: 10.1007/s11901-020-00530-0
17
Janet Lo, Michael T. Lu, Elli A. Kim, Eric Nou, Travis R. Hallett, Jakob Park, Udo Hoffmann, Steven K. Grinspoon. Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. Open Forum Infectious Diseases 2016; 3(2) doi: 10.1093/ofid/ofw062
18
Suguru Ikeda, Takaaki Sugihara, Takuya Kihara, Yukako Matsuki, Takakazu Nagahara, Tomoaki Takata, Sonoko Kitao, Tsuyoshi Okura, Kazuhiro Yamamoto, Hajime Isomoto. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. Diagnostics 2021; 11(12) doi: 10.3390/diagnostics11122316
19
Emir Muzurović, Dimitri P. Mikhailidis, Christos Mantzoros. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021; 119 doi: 10.1016/j.metabol.2021.154770
20
Sonali Paul, Michael Charlton. Surgical Issues in NASH: Bariatric Surgery and Liver Transplantation. Current Hepatology Reports 2018; 17(4) doi: 10.1007/s11901-018-0429-3
21
Maryam Mahjoubin-Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen L. Atkin, Christos S. Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular Metabolism 2021; 50 doi: 10.1016/j.molmet.2020.101049
22
Farah Ahsan, Federico Oliveri, Harshit K Goud, Zainab Mehkari, Lubna Mohammed, Moiz Javed, Aldanah Althwanay, Ian H Rutkofsky. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Cureus 2020;  doi: 10.7759/cureus.10446
23
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacological Reviews 2024; 76(3) doi: 10.1124/pharmrev.123.001087
24
Niki Katsiki, Dimitri P Mikhailidis. Lipids: a personal view of the past decade. Hormones 2018; 17(4) doi: 10.1007/s42000-018-0058-9
25
Vasilios G. Athyros, Stergios A. Polyzos, Jiannis Kountouras, Niki Katsiki, Panagiotis Anagnostis, Michael Doumas, Christos S. Mantzoros. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology 2020; 18(2) doi: 10.2174/1570161117666190405164313
26
Panagiotis Anagnostis, Konstantina Vaitsi, Panagiota Kleitsioti, Chrysanthi Mantsiou, Konstantinos Pavlogiannis, Vasilios G. Athyros, Dimitri P. Mikhailidis, Dimitrios G. Goulis. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine 2020; 69(2) doi: 10.1007/s12020-020-02302-8
27
Christian L. Horn, Amilcar L. Morales., Christopher Savard, Geoffrey C Farrell, George N. Ioannou. Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH. Hepatology Communications 2022; 6(1) doi: 10.1002/hep4.1801
28
Weiqin Zhang, Ting Shao, Caiyan Wang, Shaogui Wang, Lin An. Advances in pharmacological interventions for hepatic fibrosis: from pathogenic mechanisms to novel therapeutic targets. Annals of Medicine 2026; 58(1) doi: 10.1080/07853890.2026.2613502
29
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. American Journal of Physiology-Gastrointestinal and Liver Physiology 2017; 312(6) doi: 10.1152/ajpgi.00101.2017
30
Dilek Yazıcı, Selin Çakmak Demir, Havva Sezer. Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology 2024; 1460 doi: 10.1007/978-3-031-63657-8_14
31
George N. Ioannou, Charles S. Landis, Ga‐Young Jin, W. Geoffrey Haigh, Geoffrey C. Farrell, Rahul Kuver, Sum P. Lee, Christopher Savard. Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. Hepatology Communications 2019; 3(6) doi: 10.1002/hep4.1348
32
Vasilios Gabriel Athyros. Multifactorial treatment of diabetic patients with cardiovascular disease to maximize results. Journal of Diabetes and its Complications 2021; 35(6) doi: 10.1016/j.jdiacomp.2021.107904
33
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8) doi: 10.1016/j.metabol.2016.05.003
34
Francesca Cortese, Michele Gesualdo, Annamaria Cortese, Santa Carbonara, Fiorella Devito, Annapaola Zito, Gabriella Ricci, Pietro Scicchitano, Marco Matteo Ciccone. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacological Research 2016; 107 doi: 10.1016/j.phrs.2016.02.012
35
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis, Christos Mantzoros. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71 doi: 10.1016/j.metabol.2017.02.014
36
Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran. Non-alcoholic Fatty Liver Disease: A Clinical Update. Journal of Clinical and Translational Hepatology 2017; (XX) doi: 10.14218/JCTH.2017.00013
37
Roberta de Pádua Borges, Nathália Abi Habib Degobi, Marcello Casaccia Bertoluci. Choosing statins: a review to guide clinical practice. Archives of Endocrinology and Metabolism 2020;  doi: 10.20945/2359-3997000000306
38
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis. Off target effects of statins shape total mortality?. Journal of Drug Assessment 2016; 5(1) doi: 10.3109/21556660.2016.1168302
39
Pakkapon Rattanachaisit, Paweena Susantitaphong, Kessarin Thanapirom, Roongruedee Chaiteerakij, Piyawat Komolmit, Pisit Tangkijvanich, Sombat Treeprasertsuk. Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Asian Biomedicine 2018; 12(1) doi: 10.1515/abm-2018-0026
40
Yongfeng Song, Junjun Liu, Ke Zhao, Ling Gao, Jiajun Zhao. Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases. Cell Metabolism 2021; 33(10) doi: 10.1016/j.cmet.2021.09.001
41
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis. Clinics and Research in Hepatology and Gastroenterology 2022; 46(4) doi: 10.1016/j.clinre.2021.101842
42
Weiwei Dai, Baohong Xu, Peng Li, Junhua Weng. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. American Journal of Therapeutics 2023; 30(1) doi: 10.1097/MJT.0000000000001499
43
Samarth Siddharth Patel, Mohammad Shadab Siddiqui. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. Drugs 2019; 79(1) doi: 10.1007/s40265-018-1040-1
44
Nguyen Pham, Jihane N. Benhammou. Statins in Chronic Liver Disease: Review of the Literature and Future Role. Seminars in Liver Disease 2024; 44(02) doi: 10.1055/a-2319-0694
45
Niki Katsiki, Genovefa Kolovou, Pablo Perez-Martinez, Dimitri P. Mikhailidis. Dyslipidaemia in the elderly: to treat or not to treat?. Expert Review of Clinical Pharmacology 2018; 11(3) doi: 10.1080/17512433.2018.1425138
46
Ricardo Amorim, Pedro Soares, Daniel Chavarria, Sofia Benfeito, Fernando Cagide, José Teixeira, Paulo J. Oliveira, Fernanda Borges. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities. European Journal of Medicinal Chemistry 2024; 277 doi: 10.1016/j.ejmech.2024.116723
47
Won Dong Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim. Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. European Journal of Gastroenterology & Hepatology 2020; 32(12) doi: 10.1097/MEG.0000000000001665
48
Nicholas W.S. Chew, Mark D. Muthiah, Arun J. Sanyal. Cardiovascular Endocrinology and Metabolism. 2023;  doi: 10.1016/B978-0-323-99991-5.00003-6
49
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. NAFLD and Statins. Digestive Diseases and Sciences 2020; 65(10) doi: 10.1007/s10620-020-06505-x
50
D. van der Graaff, W.J. Kwanten, S.M. Francque. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Medical Hypotheses 2019; 122 doi: 10.1016/j.mehy.2018.11.014
51
Mazen Noureddin, Alice Zhang, Rohit Loomba. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opinion on Emerging Drugs 2016; 21(3) doi: 10.1080/14728214.2016.1220533
52
Joost Boeckmans, Alessandra Natale, Karolien Buyl, Vera Rogiers, Joery De Kock, Tamara Vanhaecke, Robim M. Rodrigues. Human-based systems: Mechanistic NASH modelling just around the corner?. Pharmacological Research 2018; 134 doi: 10.1016/j.phrs.2018.06.029
53
George N. Ioannou, Sum P. Lee, Peter S. Linsley, Vivian Gersuk, Matthew M. Yeh, Yen‐Ying Chen, Yi‐Jen Peng, Moumita Dutta, Gabby Mascarinas, Bruk Molla, Julia Yue Cui, Christopher Savard. Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. Hepatology Communications 2022; 6(4) doi: 10.1002/hep4.1858
54
Yongxin Li, Changying Zhao, Jun Wang, Tao Shi. The correlation between the trajectory of plasma atherosclerosis-inducing index in the examination population and the risk of developing metabolic dysfunction-associated steatotic liver disease. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1708671
55
Omar Alkasabrah, Dhruvi Kalpesh Joshi, Abdullah Hafeez, Siddharth Pravin Agrawal, William H. Frishman, Wilbert S. Aronow. Statins and the Cardio-Hepatic Axis: Balancing Cardiovascular Protection with Liver Disease Safety. Cardiology in Review 2025;  doi: 10.1097/CRD.0000000000001122
56
Bubu A. Banini, Arun J. Sanyal. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current Opinion in Gastroenterology 2017; 33(3) doi: 10.1097/MOG.0000000000000356
57
Chattraya Ngamlerst, Arunwan Udomkasemsab, Ratchanee Kongkachuichai, Karunee Kwanbunjan, Chaowanee Chupeerach, Pattaneeya Prangthip. The potential of antioxidant-rich Maoberry (Antidesma bunius) extract on fat metabolism in liver tissues of rats fed a high-fat diet. BMC Complementary and Alternative Medicine 2019; 19(1) doi: 10.1186/s12906-019-2716-0
58
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clinical and Molecular Hepatology 2022; 28(3) doi: 10.3350/cmh.2022.0186
59
C. Moctezuma-Velázquez. Current treatment for non-alcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2018; 83(2) doi: 10.1016/j.rgmxen.2018.05.014
60
Sven M. Francque, W. J. Kwanten, D. van der Graaff. Portal Hypertension in NASH: Is It Different from Other Aetiologies?. Current Hepatology Reports 2019; 18(2) doi: 10.1007/s11901-019-00459-z
61
Diana Barb, Kenneth Cusi. Reply to “statins and non-alcoholic steatohepatitis”. Metabolism 2017; 66 doi: 10.1016/j.metabol.2016.10.004
62
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, Tian Lan, Bing Liu. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action. Molecules 2024; 29(8) doi: 10.3390/molecules29081859
63
Connie B. Newman, David Preiss, Jonathan A. Tobert, Terry A. Jacobson, Robert L. Page, Larry B. Goldstein, Clifford Chin, Lisa R. Tannock, Michael Miller, Geetha Raghuveer, P. Barton Duell, Eliot A. Brinton, Amy Pollak, Lynne T. Braun, Francine K. Welty. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019; 39(2) doi: 10.1161/ATV.0000000000000073
64
B. V. M. Dasari, A. Pathanki, J. Hodson, K. J. Roberts, R. Marudanayagam, D. F. Mirza, J. Isaac, R. P. Sutcliffe, P. Muiesan. Propensity-matched analysis of the influence of perioperative statin therapy on outcomes after liver resection. BJS Open 2019; 3(4) doi: 10.1002/bjs5.50155
65
Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu, Yunlun Li, Kusum Kharbanda. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. BioMed Research International 2020; 2020(1) doi: 10.1155/2020/4020249
66
Somaya Albhaisi, Arun J. Sanyal. Comprehensive Pharmacology. 2022;  doi: 10.1016/B978-0-12-820472-6.00121-3
67
Xiaoyan Zhang, Jingxin Li, Tiancai Liu, Min Zhao, Baozhu Liang, Hong Chen, Zhen Zhang, Ihtisham Bukhari. Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery. Disease Markers 2022; 2022 doi: 10.1155/2022/4369329
68
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitis. Journal of Hepatology 2016; 64(1) doi: 10.1016/j.jhep.2015.09.021
69
Asahiro Morishita, Kyoko Oura, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Tingting Shi, Takashi Himoto, Miwa Tatsuta, Akio Moriya, Tomonori Senoo, Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Masafumi Ono, Tsutomu Masaki. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatology International 2023; 17(3) doi: 10.1007/s12072-022-10453-1
70
Kaveh Hajifathalian, Zaid Tafesh, Russell Rosenblatt, Sonal Kumar, Edwin A. Homan, Reem Z. Sharaiha, David E. Cohen, Robert S. Brown, Brett E. Fortune. Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2022; 56(2) doi: 10.1097/MCG.0000000000001503
71
Xianhua Liao, Qianqian Ma, Tingfeng Wu, Congxiang Shao, Yansong Lin, Yanhong Sun, Shiting Feng, Wei Wang, Junzhao Ye, Bihui Zhong. Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2022;  doi: 10.2147/DMSO.S356371
72
Katherine T. Brunner, Cameron J. Henneberg, Robert M. Wilechansky, Michelle T. Long. Nonalcoholic Fatty Liver Disease and Obesity Treatment. Current Obesity Reports 2019; 8(3) doi: 10.1007/s13679-019-00345-1
73
Michele Finotti, Maurizio Romano, Pasquale Auricchio, Michele Scopelliti, Marco Brizzolari, Ugo Grossi, Marco Piccino, Stefano Benvenuti, Giovanni Morana, Umberto Cillo, Giacomo Zanus. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. Journal of Personalized Medicine 2021; 11(6) doi: 10.3390/jpm11060499
74
Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D. Goodman, Keith Lindor. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018; 68(1) doi: 10.1002/hep.29724
75
Henrik H. Hansen, Michael Feigh, Sanne S. Veidal, Kristoffer T. Rigbolt, Niels Vrang, Keld Fosgerau. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22(11) doi: 10.1016/j.drudis.2017.06.007
76
Robert Gish, Jian-Gao Fan, Zahra Dossaji, Jeanne Fichez, Tooba Laeeq, Magnus Chun, Jerome Boursier. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. Hepatology International 2024; 18(S2) doi: 10.1007/s12072-024-10698-y
77
Vasilios G. Athyros, Charalambos Koumaras, George Sfikas. Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments. Current Vascular Pharmacology 2021; 19(6) doi: 10.2174/1570161119666201215141414
78
Thaninee Prasoppokakorn. Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Livers 2025; 5(1) doi: 10.3390/livers5010004
79
Fabio Nascimbeni, Elisa Pellegrini, Simonetta Lugari, Alberto Mondelli, Serena Bursi, Giovanna Onfiani, Francesca Carubbi, Amedeo Lonardo. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. Atherosclerosis 2019; 284 doi: 10.1016/j.atherosclerosis.2019.02.028
80
Somaya Albhaisi, Arun Sanyal. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Research 2018; 7 doi: 10.12688/f1000research.14421.1
81
Yaron Rotman, Arun J Sanyal. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017; 66(1) doi: 10.1136/gutjnl-2016-312431
82
Maria Apostolopoulou, Michael Roden. Nicht-alkoholische Fettlebererkrankung. 2022;  doi: 10.1007/978-3-662-62484-5_20
83
Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Eric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, Mohammad Hassan Murad, Mazen Noureddin. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2019; 17(4) doi: 10.1016/j.cgh.2018.06.011
84
Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatology Research 2021; 51(10) doi: 10.1111/hepr.13688
85
May G. Akl, Scott B. Widenmaier. Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. Frontiers in Cell and Developmental Biology 2023; 10 doi: 10.3389/fcell.2022.1089124
86
Athanasia Mitsala, Christos Tsalikidis, Konstantinos Romanidis, Michail Pitiakoudis. Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing?. Current Oncology 2022; 29(7) doi: 10.3390/curroncol29070356
87
Niki Katsiki, Vasilios G Athyros. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. Current Medical Research and Opinion 2019; 35(7) doi: 10.1080/03007995.2019.1589152
88
Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos. Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology 2022; 14(1): 119-139 doi: 10.4254/wjh.v14.i1.119
89
Frank Tacke. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opinion on Investigational Drugs 2018; 27(3) doi: 10.1080/13543784.2018.1442436
90
Vasilios G. Athyros, Dimitri P. Mikhailidis. High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. Journal of Diabetes and its Complications 2016; 30(1) doi: 10.1016/j.jdiacomp.2015.07.012
91
Sarita Agrawal, Shreya Panda, Jyotshna Kashibhatla. Management of Menopause. 2024;  doi: 10.1007/978-981-96-0239-1_13
92
Abdul M. Oseini, Arun J. Sanyal. Therapies in non‐alcoholic steatohepatitis (NASH). Liver International 2017; 37(S1) doi: 10.1111/liv.13302
93
Nicholas W. S. Chew, Cheng Han Ng, Mark Dhinesh Muthiah, Arun J. Sanyal. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Current Atherosclerosis Reports 2022; 24(7) doi: 10.1007/s11883-022-01027-5
94
Maria-Styliani Kalogirou, Dimitrios Patoulias, Anna-Bettina Haidich, Evangelos Akriviadis, Emmanouil Sinakos. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2021; 45(3) doi: 10.1016/j.clinre.2020.10.012
95
Gregor Lorbek, Žiga Urlep, Damjana Rozman. Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease. Pharmacogenomics 2016; 17(11) doi: 10.2217/pgs-2016-0047
96
Scott Isaacs. Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 2023; 52(1) doi: 10.1016/j.ecl.2022.06.007
97
. 2021;  doi: 10.70675/84e2e5fdze227z4f31zb2dez9d36beb885a4
98
Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis. Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention. The American Journal of Cardiology 2016; 117(2) doi: 10.1016/j.amjcard.2015.11.001
99
Nikos Lazaridis, Emmanuel Tsochatzis. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology 2017; 11(4) doi: 10.1080/17474124.2017.1293523
100
Stefano Ciardullo, Gianluca Perseghin. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism 2021; 121 doi: 10.1016/j.metabol.2021.154752
101
Bo Zhu, Hao Wu, Kathryn S. Li, Shahram Eisa-Beygi, Bandana Singh, Diane R. Bielenberg, Wendong Huang, Hong Chen. Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis. Vascular Pharmacology 2024; 154 doi: 10.1016/j.vph.2023.107249
102
Connie B. Newman. Safety of Statins and Nonstatins for Treatment of Dyslipidemia. Endocrinology and Metabolism Clinics of North America 2022; 51(3) doi: 10.1016/j.ecl.2022.01.004
103
Amr Y. Zakaria, Rehab Badawi, Hasnaa Osama, Mona A. Abdelrahman, Asmaa M. El-Kalaawy. A Comparative Study of N-Acetyl Cysteine, Rosuvastatin, and Vitamin E in the Management of Patients with Non-Alcoholic Steatohepatitis: A Randomized Controlled Trial. Pharmaceuticals 2025; 18(5) doi: 10.3390/ph18050650
104
Eric P. Stahl, Devinder S. Dhindsa, Suegene K. Lee, Pratik B. Sandesara, Naga P. Chalasani, Laurence S. Sperling. Nonalcoholic Fatty Liver Disease and the Heart. Journal of the American College of Cardiology 2019; 73(8) doi: 10.1016/j.jacc.2018.11.050
105
Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi. Statins for treatment of fatty liver disease: Recent advances. World Chinese Journal of Digestology 2023; 31(16) doi: 10.11569/wcjd.v31.i16.659
106
Mark D. Muthiah, Arun J. Sanyal. Current management of non‐alcoholic steatohepatitis. Liver International 2020; 40(S1) doi: 10.1111/liv.14355
107
Theodora Griva, Chrysoula Boutari, Konstantinos Tziomalos, Michael Doumas, Asterios Karagiannis, Vasilios G. Athyros. Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. The Open Hypertension Journal 2017; 9(1) doi: 10.2174/1876526201709010001
108
Vasilios G Athyros. Statins for the Treatment of Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome. Journal of Diabetes, Metabolic Disorders & Control 2016; 3(1) doi: 10.15406/jdmdc.2016.03.00057
109
Mohamed Abdallah, Landon Brown, John Provenza, Raseen Tariq, Smitha Gowda, Ashwani K. Singal. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Annals of Hepatology 2022; 27(6) doi: 10.1016/j.aohep.2022.100738
110
Practical Diabetes Care. 2018;  doi: 10.1002/9781119052210.ch13
111
V. G. Athyros, N. Katsiki, D. P. Mikhailidis. Letter: statins and cirrhosis. Alimentary Pharmacology & Therapeutics 2017; 46(11-12) doi: 10.1111/apt.14355
112
Vimala Ananthy, Raman Palanyswamy Priyadharsini, Umamaheswari Subramanian. Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive Review. SBV Journal of Basic, Clinical and Applied Health Science 2021; 4(2) doi: 10.5005/jp-journals-10082-03111
113
Mohamad Kareem Marrache, Don C. Rockey. Statins for treatment of chronic liver disease. Current Opinion in Gastroenterology 2021; 37(3) doi: 10.1097/MOG.0000000000000716
114
George Zacharia, Anu Jacob, Manivarnan Karichery, Abhishek Sasidharan. Impact of statins in the liver: A bane or a boon?. Canadian Liver Journal 2024; 7(4) doi: 10.3138/canlivj-2023-0028
115
Satoshi Shinozaki, Toshiyuki Tahara, Kouichi Miura, Alan Kawarai Lefor, Hironori Yamamoto. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study. Life 2023; 13(6) doi: 10.3390/life13061327
116
Umair Iqbal, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed. Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases 2018; 6(4) doi: 10.3390/diseases6040087
117
Chrysoula Boutari, Panagiotis D. Pappas, Dimitrios Anastasilakis, Christos S. Mantzoros. Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinical Nutrition 2022; 41(10) doi: 10.1016/j.clnu.2022.08.001
118
Rashid Ali Khan, Uma Bhandari, Prem Kapur, Abhinav Jain, Farrukh Farah. Effects of rosuvastatin (added to hypocaloric diet) on serum periostin, adiponectin, proinflammtory cytokines levels and hepatic steatosis in non-alcoholic fatty liver disease patients with dyslipidemia. Clinical Epidemiology and Global Health 2019; 7(1) doi: 10.1016/j.cegh.2017.12.010
119
Sergi Guixé-Muntet, Chang-Peng Zhu, Wei-Fen Xie, Jordi Gracia-Sancho. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020; 215 doi: 10.1016/j.pharmthera.2020.107626
120
Caroline Chong Nguyen, Denis Duboc, Dominique Rainteau, Harry Sokol, Lydie Humbert, Philippe Seksik, Adèle Bellino, Hendy Abdoul, Naïm Bouazza, Jean-Marc Treluyer, Malika Saadi, Karim Wahbi, Heithem Soliman, Benoit Coffin, André Bado, Maude Le Gall, Olivier Varenne, Henri Duboc. Circulating bile acids concentration is predictive of coronary artery disease in human. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-02144-y
121
Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan Petakov. Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. Current Vascular Pharmacology 2021; 19(5) doi: 10.2174/1570161118666201008162537
122
Amr Y. Zakaria, Rehab Badawi, Hasnaa Osama, Mona A. Abdelrahman, Asmaa M. El-Kalaawy. New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial. Clinical Therapeutics 2025; 47(8) doi: 10.1016/j.clinthera.2025.05.006
123
C. Moctezuma-Velázquez. Tratamiento actual de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 2018; 83(2) doi: 10.1016/j.rgmx.2017.10.003
124
Matthew Kappus, Manal Abdelmalek. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clinics in Liver Disease 2017; 21(2) doi: 10.1016/j.cld.2016.12.006
125
David Niederseer, Bernhard Wernly, Elmar Aigner, Felix Stickel, Christian Datz. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. Journal of Clinical Medicine 2021; 10(3) doi: 10.3390/jcm10030467
126
Prashanth Francis, Lisa M. Forman. Statins Show Promise Against Progression of Liver Disease. Clinical Liver Disease 2021; 18(6) doi: 10.1002/cld.1143
127
Markus Ammann, Patrick Starlinger. Liver Regeneration Techniques in Hepatic Surgery. 2026;  doi: 10.1007/978-3-032-10997-2_3
128
Sunetra Mondal, Amarta Shankar Chowdhury, Rajat Deb, Debmalya Sanyal. Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future. Diabetology International 2025; 16(4) doi: 10.1007/s13340-025-00833-x
129
Vasilios G. Athyros, Niki Katsiki, Dimitri P. Mikhailidis. Statins and non-alcoholic steatohepatitis. Metabolism 2017; 66 doi: 10.1016/j.metabol.2016.10.006
130
Atul D. Bali, Akiva Rosenzveig, William H. Frishman, Wilbert S. Aronow. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. Cardiology in Review 2024; 32(5) doi: 10.1097/CRD.0000000000000537
131
Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios G. Athyros. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. Current Vascular Pharmacology 2019; 17(5) doi: 10.2174/157016111705190703102816
132
Carlos Moctezuma-Velázquez, Juan G. Abraldes, Aldo J. Montano-Loza. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. Current Treatment Options in Gastroenterology 2018; 16(2) doi: 10.1007/s11938-018-0180-4
133
Kensuke Kitsugi, Hidenao Noritake, Moe Matsumoto, Tomohiko Hanaoka, Masahiro Umemura, Maho Yamashita, Shingo Takatori, Jun Ito, Kazuyoshi Ohta, Takeshi Chida, Takafumi Suda, Kazuhito Kawata. Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathway. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2023; 1869(7) doi: 10.1016/j.bbadis.2023.166750
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.